SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a medical device technology company focused on
unmet needs in global health, today announced that it will issue
financial results for its second quarter fiscal year 2021, ended
September 30, 2020, at 4:15 pm Eastern time on Wednesday, October 28,
2020.
Management will host a conference call on Wednesday, October 28, 2020 at 4:30 pm eastern time to review financial results
and recent corporate developments. Following management's formal
remarks, there will be a question and answer session.
Interested parties can register for the conference by navigating
to https://dpregister.com/sreg/10149369/dbcc2bc6ad. Please
note that registered participants will receive their dial in number
upon registration.
Interested parties
without internet access or unable to pre-register may dial in by
calling:
|
PARTICIPANT DIAL IN
(TOLL FREE):
|
1-844-836-8741
|
PARTICIPANT
INTERNATIONAL DIAL IN:
|
1-412-317-5442
|
All callers should
ask for the Aethlon Medical, Inc. conference call.
|
A replay of the call will be available approximately one hour
after the end of the call through November
4, 2020. The replay can be accessed via Aethlon Medical's
website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international) or Canada Toll Free at 1-855-669-9658. The replay
conference ID number is 10149369.
About Aethlon Medical, Inc.
Aethlon Medical is focused on addressing unmet needs in global
health. The Aethlon Hemopurifier® is a clinical-stage
immunotherapeutic device designed to combat cancer and
life-threatening viral infections. In cancer, the Hemopurifier®
depletes the presence of circulating tumor-derived exosomes that
promote immune suppression, seed the spread of metastasis and
inhibit the benefit of leading cancer therapies. The Hemopurifier®
is an FDA designated "Breakthrough Device" related to the treatment
of individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease cancer. The Hemopurifier
also holds a Breakthrough Device designation related to
life-threatening viruses that are not addressed with approved
therapies.
Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which
is focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disease progression. Additional
information can be found online at www.AethlonMedical.com and
www.ExosomeSciences.com.
Company Contact:
Jim
Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan
Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:http://www.prnewswire.com/news-releases/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-october-28-2020-301154411.html
SOURCE Aethlon Medical, Inc.